Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Presented at American Society of Hematology Annual Meeting

Corporate news announcement processed and transmitted by Hugin AS.
The issuer is solely responsible for the content of this
announcement.
----------------------------------------------------------------------
--------------

BETHESDA, MD, December 3, 2008 -- Micromet, Inc. (Nasdaq: MITI), a
biopharmaceutical company developing novel, proprietary antibodies
for the treatment of cancer, inflammation and autoimmune diseases,
will host a webcast and conference call on, Monday, December 8, 2008,
at 2:00 p.m. Eastern Time (8:00 p.m. Central European Time) to
discuss the blinatumomab data that were presented at the American
Society of Hematology (ASH) meeting.

To access the webcast and view the powerpoint presentation, please
log on to: http://webcasts.micromet-inc.com. To participate in the
conference call, dial 866-700-7441 (U.S.) or 617-213-8839
(international), passcode: 39298646.

A replay of the call will be available from 4:00 p.m. Eastern Time on
December 8, 2008 (10:00 p.m. Central European Time) through Monday,
December 22, 2008. The replay number is 888-286-8010 (U.S.) or
617-801-6888 (international), passcode: 27748310.

About Micromet, Inc.

Micromet, Inc. (www.micromet-inc.com) is a biopharmaceutical company
with offices in Bethesda, Maryland and Munich, Germany. The Company
is developing novel, proprietary antibodies for the treatment of
cancer, inflammation and autoimmune diseases. The Company uses its
proprietary BiTE® antibody platform to create a new class of
antibodies that specifically activate T cells from the patient's own
immune system to eliminate cancer cells or other disease-related
cells. Four of the Company's antibodies are currently in clinical
trials, with the remainder of its product pipeline in preclinical
development. The Company's lead program is a BiTE antibody known as
blinatumomab, or MT103. It is in a phase 2 clinical trial for the
treatment of patients with acute lymphoblastic leukemia and a phase 1
clinical trial for the treatment of patients with non-Hodgkin's
lymphoma. Micromet is developing blinatumomab in collaboration with
MedImmune, a subsidiary of AstraZeneca plc. Micromet's second BiTE
antibody in clinical development is MT110, which targets the
epithelial cell adhesion molecule (EpCAM). The Company owns all
rights to MT 110, which is currently in a phase 1 clinical trial for
the treatment of patients with solid tumors. The Company's third
clinical stage antibody is

(more)

adecatumumab, also known as MT201, a conventional human monoclonal
antibody that targets EpCAM-expressing solid tumors. Micromet is
developing adecatumumab in collaboration with Merck Serono in a phase
1b clinical trial evaluating adecatumumab in combination with
docetaxel for the treatment of patients with metastatic breast
cancer. Micromet has licensed a fourth clinical stage antibody,
MT293, to TRACON Pharmaceuticals, Inc. MT293 is being developed in a
phase 1 clinical trial for the treatment of patients with cancer. The
Company's preclinical programs include MT203, which is being
developed in collaboration with Nycomed. MT203 is a traditional human
antibody neutralizing the activity of granulocyte/macrophage colony
stimulating factor (GM-CSF), which has potential applications in the
treatment of inflammatory and autoimmune diseases, such as rheumatoid
arthritis, psoriasis, or multiple sclerosis. Additional BiTE
antibodies, targeting CEA, CD33, Her2, EGFR and MCSP, respectively,
are in different stages of preclinical development.

Forward-Looking Statements

This release contains certain forward-looking statements that involve
risks and uncertainties that could cause actual results to be
materially different from historical results or from any future
results expressed or implied by such forward-looking statements.
These forward-looking statements include statements regarding the
efficacy and intended utilization of our product candidates and the
development of our BiTE antibody technology. You are urged to
consider statements that include the words "may," "potential," or the
negative of those words or other similar words to be uncertain and
forward-looking. Factors that may cause actual results to differ
materially from any future results expressed or implied by any
forward-looking statements include the risk that product candidates
that appeared promising in early research, preclinical studies or
clinical trials do not demonstrate safety and/or efficacy in
subsequent clinical trials, the risk that encouraging results from
early research, preclinical studies or clinical trials may not be
confirmed upon further analysis of the detailed results of such
research, preclinical study or clinical trial, and the risk that
additional information relating to the safety, efficacy or
tolerability of our product candidates may be discovered upon further
analysis of preclinical or clinical trial data. These factors and
others are more fully discussed in Micromet's Quarterly Report on
Form 10-Q for the fiscal quarter ended September 30, 2008, filed with
the SEC on November 6, 2008, as well as other filings by the company
with the SEC.

Any forward-looking statements are made pursuant to Section 27A of
the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as

(more)

amended, and, as such, speak only as of the date made. Micromet, Inc.
undertakes no obligation to publicly update any forward-looking
statements, whether as a result of new information, future events or
otherwise.

# # #

Contact Information

US Media: European Media:
Andrea tenBroek/Chris Stamm Ludger Wess
(781)-684-0770 +49 (40) 8816 5964
micromet@schwartz-pr.com ludger@akampion.com

US Investors: European Investors:
Susan Noonan Ines-Regina Buth
(212) 966-3650 +49 (30) 2363 2768
susan@sanoonan.com ines@akampion.com

--- End of Message ---

Micromet Inc.
6707 Democracy Boulevard, Suite 505 Bethesda USA

WKN:
A0JMQD; ISIN: US59509C1053;
Listed: Xetra Stars in Frankfurter Wertpapierbörse;
Copyright © Hugin AS 2008. All rights reserved.